Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEKTRA: TAK-935 (OV935) as Adjunctive Therapy in Pediatric Developmental and/or Epileptic Encephalopathies
2018-002484-25Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epileptic encephalopathy, Dravet syndrome and Lennox-Gastaut syndrome (LGS) comparing TAK-935 adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Nov 2018; status: completed.
02
Drugs
soticlestat
03
Conditions
epileptic encephalopathyDravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2018-002484-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002484-25.